
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Pediatr.
Sec. Neonatology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1456818
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Neonatal Diabetes Mellitus (NDM) is a rare disease, whose prevalence is 1 in 90,000 to 160,000 live births, with 31% of all preterm diagnoses linked to monogenic causes. NDM is differentiated into transient, permanent, and syndromic NDM. 40% of patients diagnosed with NDM are responsive to oral sulfonylureas (SU) due to expressed mutations of the ABCC8 or KCNJ11 genes coding for adenosine triphosphate-sensitive potassium channel (KATP) subunits in pancreatic beta (ꞵ) cells. SUs bind to the sulfonylurea receptor 1 (SUR1) subunit, closing the KATP channel and increasing insulin secretion. Although SUs remain the mainstay of NDM treatment, these medications are traditionally only dosed and approved for hyperglycemic control in adults. Current treatment regimens suggest a high dose, 1 mg/kg/day, for patients with KCNJ11 neonatal diabetes.Our male neonate was born at 27 weeks and 1020 grams via emergency cesarean section due to complete placenta previa and maternal hemorrhage following perinatal betamethasone administration. Neonatal resuscitation was required. During resuscitation, the patient was intubated and found to be hyperglycemic. He was subsequently started on Regular Humulin at 0.1 units/kg/dose subcutaneously (SQ) and increased to 0.2 units/kg/dose SQ before transfer to our facility on day of life (DOL) 19. In our Neonatal Intensive Care Unit (NICU), the patient was transitioned to an insulin drip due to difficulty obtaining and administering the appropriate, but minuscule, SQ insulin doses. Genetic testing was positive for a pathogenic variant c.679G>A (p.Glu227Lys) in KCNJ11; therefore, glyburide was started at 0.1 mg/kg/dose twice a day (BID) on DOL 54, resulting in euglycemia. Hyperglycemia recurred after an initial attempt to wean; however, a subsequent wean on DOL 70 was successful in maintaining euglycemia without insulin or glyburide for 48 hours prior to discharge on DOL 78.This case report describes the unique and complicated clinical course of a premature neonate with an initially undifferentiated class of NDM requiring a microdose, a fraction of a regular dose, based approach to both insulin and SU-based management. This report offers a concise recount of the applied diagnostic and therapeutic procedures while suggesting a decision tree for future NDM management in neonates.
Keywords: Neonatal diabetes mellitus, KCNJ11 mutations, Insulin, neonatal endocrinology, Genetic Testing, NICu, preterm, Sulfonylurea
Received: 29 Jun 2024; Accepted: 25 Mar 2025.
Copyright: © 2025 Perera, Jensen, Sherwood and Patel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Brooke Jensen, Carilion Roanoke Memorial Hospital, Roanoke, Virginia, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.